TransCode Therapeutics Inc Stock

$3.67

5.66% day before yesterday

Nasdaq, Dec 27, 10:00 pm CET

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

TransCode Therapeutics Inc Stock price

$3.67

-105,596.33 100.00% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

-0.22 5.66%

ISIN

US89357L1052

Symbol

RNAZ

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Key metrics

Market capitalization	$2.56m
Enterprise Value	$830.00k
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
P/B ratio (TTM) P/B ratio	1.16
Revenue (TTM) Revenue	$0.00
EBIT (operating result TTM) EBIT	$-14.63m
Free Cash Flow (TTM) Free Cash Flow	$-15.87m
Cash position	$1.88m
EPS (TTM) EPS	$-265.83
P/S forward	8.53
EV/Sales forward	2.77
Short interest	4.31%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

TransCode Therapeutics Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast TransCode Therapeutics Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast TransCode Therapeutics Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from TransCode Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Sep '24		+/- %
Revenue	- -	- 100%
- Direct Costs	0.55 0.55	34% 34% -
Gross Profit	-0.55 -0.55	34% 34% -
- Selling and Administrative Expenses	4.14 4.14	51% 51% -
- Research and Development Expense	9.38 9.38	19% 19% -
EBITDA	-14 -14	31% 31% -
- Depreciation and Amortization	0.55 0.55	34% 34% -
EBIT (Operating Income) EBIT	-15 -15	30% 30% -
Net Profit	-15 -15	24% 24% -

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

TransCode Therapeutics Inc Stock News

Neutral

PRNewsWire

●

11 days ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Approval given after Safety Review Committee (SRC) review of safety data from the three patients comprising Cohort 2 No significant safety or dose limiting toxicities reported in Cohort 2 New patients currently being evaluated for eligibility in Cohort 3 PK and PD data from Cohort 1 patients consistent with preclinical and Phase 0 trial results BOSTON , Dec. 18, 2024 /PRNewswire/ -- TransCode T...

Neutral

GlobeNewsWire

●

29 days ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

BOSTON, Nov. 29, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved an effective time at 12:01 a.m. Eastern Standard Time December 4, 2024, for its 1-for-33 reverse stock split.

Neutral

GlobeNewsWire

●

about one month ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (Nasdaq: RNAZ), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that it has entered into a securities purchase agreement with certain institutional investors. The aggregate gross cash proceeds are expected to be approximately $8 million before deducting fees to ...

More TransCode Therapeutics Inc News

Company Profile

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

Head office	United States
CEO	Thomas Fitzgerald
Employees	10
Founded	2016
Website	www.transcodetherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now